Novel curcumin-loaded human serum albumin nanoparticles surface functionalized with folate: Characterization and in vitro/vivo evaluation

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 2643-2649

  Song, Zhiwang ^a   Lu, Yonglin ^a   Zhang, Xia ^a   Wang, Haiping ^a   Han, Junyi ^a   Dong, Chunyan ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Curcumin; Folate; HSA nanoparticles; Pharmacokinetic parameters

Indexed keywords

CURCUMIN; FOLIC ACID; HUMAN SERUM ALBUMIN; NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COLON CANCER; CONJUGATION; CONTROLLED STUDY; DISPERSION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG STABILITY; DRUG STORAGE; ELIMINATION HALF-LIFE; ENCAPSULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HT-29 CELL LINE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FOLIC ACID; HT29 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; RATS; SERUM ALBUMIN; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84983287964     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S112039     Document Type: Article

References (24)

1. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14(2):141–153.
2. Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int. 2014;2014:186864.
3. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010;17(3):190–197.
4. Kumar G, Mittal S, Sak K, Tuli HS. Molecular mechanisms underlying chemopreventive potential of curcumin: current challenges and future perspectives. Life Sci. 2016;148:313–328.
5. Wegiel LA, Zhao Y, Mauer LJ, Edgar KJ, Taylor LS. Curcumin amorphous solid dispersions: the influence of intra and intermolecular bonding on physical stability. Pharm Dev Technol. 2014;19(8):976–986.
6. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
7. Liu W, Zhai Y, Heng X, et al. Oral bioavailability of curcumin: problems and advancements. J Drug Target. 2016:1–9.
8. Hani U, Shivakumar HG. Solubility enhancement and delivery systems of curcumin a herbal medicine: a review. Curr Drug Deliv. 2014;11(6):792–804.
9. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35(10):3365–3383.
10. Siddiqui IA, Sanna V. Impact of nanotechnology on delivery of natural products for cancer prevention and therapy. Mol Nutr Food Res. 2016;60(6):1330–1341.
11. Mahmood K, Zia KM, Zuber M, Salman M, Anjum MN. Recent developments in curcumin and curcumin based polymeric materials for biomedical applications: a review. Int J Biol Macromol. 2015;81:877–890.
12. Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm. 2007;341(1–2):207–214.
13. Quan Q, Xie J, Gao H, et al. HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. Mol Pharm. 2011;8(5):1669–1676.
14. Stollenwerk MM, Pashkunova-Martic I, Kremser C, et al. Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation. Histochem Cell Biol. 2010;133(4):375–404.
15. Fabi A, Giannarelli D, Malaguti P, et al. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Drug Des Devel Ther. 2015;9:6177–6183.
16. Weber C, Kreuter J, Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm. 2000;196(2):197–200.
17. Ulbrich K, Michaelis M, Rothweiler F, et al. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm. 2011;406(1–2):128–134.
18. Li C, Li Y, Gao Y, et al. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous? Int J Pharm. 2014;468(1–2):15–25.
19. Zhang L, Hou S, Mao S, Wei D, Song X, Lu Y. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm. 2004;287(1–2):155–162.
20. Zhao L, Du J, Duan Y, et al. Curcumin loaded mixed micelles composed of Pluronic P123 and F68: preparation, optimization and in vitro characterization. Colloids Surf B Biointerfaces. 2012;97:101–108.
21. Licciardi M, Paolino D, Celia C, Giammona G, Cavallaro G, Fresta M. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs. Biomaterials. 2010;31(28):7340–7354.
22. Mehta AK, Yadav KS, Sawant KK. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Deliv. 2007;4(3):185–193.
23. Lu H, Li B, Kang Y, et al. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol. 2007;59(2):175–181.
24. Zhang XY, Lu WY. Recent advances in lymphatic targeted drug delivery system for tumor metastasis. Cancer Biol Med. 2014;11(4):247–254.